Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Medicine | 11 | 2024 | 40 | 3.300 |
Why?
|
| Lung Neoplasms | 17 | 2023 | 583 | 2.810 |
Why?
|
| Bronchoscopy | 14 | 2022 | 86 | 2.480 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2023 | 147 | 1.650 |
Why?
|
| Tracheostomy | 4 | 2021 | 36 | 1.620 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 3 | 2020 | 14 | 1.030 |
Why?
|
| Pleurodesis | 4 | 2019 | 9 | 1.010 |
Why?
|
| Respiratory Insufficiency | 2 | 2020 | 148 | 0.920 |
Why?
|
| Betacoronavirus | 3 | 2020 | 166 | 0.900 |
Why?
|
| Bronchoscopes | 2 | 2022 | 11 | 0.870 |
Why?
|
| Bronchial Diseases | 2 | 2022 | 12 | 0.870 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2023 | 17 | 0.860 |
Why?
|
| Tracheal Diseases | 2 | 2022 | 12 | 0.860 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 192 | 0.830 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 205 | 0.820 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2021 | 1506 | 0.810 |
Why?
|
| Needles | 2 | 2022 | 65 | 0.760 |
Why?
|
| Amyloidosis | 1 | 2022 | 62 | 0.740 |
Why?
|
| Pneumonia | 2 | 2021 | 281 | 0.710 |
Why?
|
| Early Detection of Cancer | 5 | 2023 | 266 | 0.710 |
Why?
|
| Pleural Diseases | 1 | 2019 | 8 | 0.660 |
Why?
|
| Sclerosing Solutions | 1 | 2019 | 6 | 0.660 |
Why?
|
| Physicians | 2 | 2023 | 440 | 0.630 |
Why?
|
| Education, Medical, Graduate | 5 | 2024 | 317 | 0.610 |
Why?
|
| Career Choice | 2 | 2020 | 120 | 0.550 |
Why?
|
| Humans | 46 | 2024 | 59395 | 0.530 |
Why?
|
| Clinical Competence | 8 | 2024 | 683 | 0.520 |
Why?
|
| Pleural Effusion, Malignant | 4 | 2019 | 10 | 0.500 |
Why?
|
| Pandemics | 4 | 2021 | 617 | 0.490 |
Why?
|
| Fellowships and Scholarships | 3 | 2024 | 98 | 0.490 |
Why?
|
| Mass Screening | 4 | 2015 | 648 | 0.470 |
Why?
|
| Radiography, Thoracic | 2 | 2015 | 110 | 0.440 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 3 | 2022 | 14 | 0.420 |
Why?
|
| Catheters, Indwelling | 4 | 2018 | 67 | 0.410 |
Why?
|
| Accreditation | 3 | 2024 | 73 | 0.390 |
Why?
|
| Hypoxia | 1 | 2012 | 112 | 0.370 |
Why?
|
| Thoracoscopy | 3 | 2019 | 23 | 0.320 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 95 | 0.320 |
Why?
|
| Consensus | 2 | 2020 | 193 | 0.310 |
Why?
|
| Teaching | 1 | 2010 | 152 | 0.310 |
Why?
|
| United States | 9 | 2024 | 7424 | 0.280 |
Why?
|
| Patient Selection | 3 | 2020 | 465 | 0.270 |
Why?
|
| Societies, Medical | 5 | 2020 | 337 | 0.270 |
Why?
|
| Lung | 2 | 2020 | 919 | 0.240 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 656 | 0.230 |
Why?
|
| Retrospective Studies | 11 | 2022 | 6088 | 0.220 |
Why?
|
| Hospitalization | 2 | 2021 | 1289 | 0.220 |
Why?
|
| Probability | 1 | 2023 | 167 | 0.210 |
Why?
|
| Suction | 1 | 2022 | 33 | 0.200 |
Why?
|
| Bronchial Thermoplasty | 1 | 2021 | 1 | 0.190 |
Why?
|
| Mediastinum | 1 | 2022 | 27 | 0.190 |
Why?
|
| Female | 20 | 2023 | 30736 | 0.190 |
Why?
|
| Talc | 2 | 2019 | 5 | 0.190 |
Why?
|
| Teacher Training | 1 | 2021 | 3 | 0.180 |
Why?
|
| Torsades de Pointes | 1 | 2021 | 6 | 0.180 |
Why?
|
| Vascular Calcification | 1 | 2021 | 22 | 0.180 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 19 | 0.180 |
Why?
|
| Learning Curve | 1 | 2021 | 30 | 0.180 |
Why?
|
| Clinical Protocols | 2 | 2020 | 136 | 0.180 |
Why?
|
| Lymph Nodes | 1 | 2022 | 215 | 0.180 |
Why?
|
| Pectoralis Muscles | 1 | 2020 | 5 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 297 | 0.180 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2020 | 1 | 0.180 |
Why?
|
| Aged | 15 | 2021 | 13421 | 0.170 |
Why?
|
| Emphysema | 1 | 2020 | 34 | 0.170 |
Why?
|
| Male | 20 | 2023 | 27760 | 0.170 |
Why?
|
| Water | 1 | 2022 | 300 | 0.170 |
Why?
|
| Specimen Handling | 1 | 2020 | 61 | 0.170 |
Why?
|
| Silver Nitrate | 1 | 2019 | 1 | 0.170 |
Why?
|
| Povidone-Iodine | 1 | 2019 | 4 | 0.170 |
Why?
|
| Tetracyclines | 1 | 2019 | 6 | 0.170 |
Why?
|
| Dexamethasone | 1 | 2021 | 200 | 0.170 |
Why?
|
| Smoking | 4 | 2014 | 826 | 0.170 |
Why?
|
| Infection Control | 1 | 2020 | 94 | 0.160 |
Why?
|
| Prostheses and Implants | 1 | 2019 | 66 | 0.160 |
Why?
|
| Pneumothorax | 1 | 2019 | 49 | 0.160 |
Why?
|
| Pulmonary Emphysema | 1 | 2019 | 99 | 0.160 |
Why?
|
| Hydrothorax | 1 | 2018 | 5 | 0.150 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 32 | 0.150 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 274 | 0.150 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 292 | 0.150 |
Why?
|
| Middle Aged | 13 | 2021 | 16324 | 0.140 |
Why?
|
| Asthma | 1 | 2021 | 460 | 0.140 |
Why?
|
| Forced Expiratory Volume | 2 | 2019 | 193 | 0.130 |
Why?
|
| Curriculum | 2 | 2020 | 560 | 0.130 |
Why?
|
| Drainage | 1 | 2017 | 150 | 0.130 |
Why?
|
| Mediastinal Neoplasms | 1 | 2016 | 17 | 0.130 |
Why?
|
| Conscious Sedation | 2 | 2016 | 38 | 0.130 |
Why?
|
| Sarcoidosis | 1 | 2016 | 30 | 0.120 |
Why?
|
| Lymphoma | 1 | 2016 | 99 | 0.120 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2516 | 0.120 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2014 | 8 | 0.110 |
Why?
|
| Anoikis | 1 | 2014 | 4 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2014 | 11 | 0.110 |
Why?
|
| Self-Assessment | 3 | 2020 | 58 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2015 | 170 | 0.110 |
Why?
|
| Body Mass Index | 2 | 2020 | 831 | 0.110 |
Why?
|
| Pleural Effusion | 1 | 2013 | 35 | 0.110 |
Why?
|
| CD24 Antigen | 1 | 2013 | 18 | 0.110 |
Why?
|
| Catheter-Related Infections | 1 | 2013 | 41 | 0.110 |
Why?
|
| Sulindac | 1 | 2012 | 5 | 0.100 |
Why?
|
| Nanotechnology | 1 | 2014 | 127 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2020 | 747 | 0.100 |
Why?
|
| Electromagnetic Phenomena | 1 | 2012 | 3 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 323 | 0.100 |
Why?
|
| Antigens, Surface | 1 | 2013 | 192 | 0.100 |
Why?
|
| Hematocrit | 1 | 2012 | 32 | 0.100 |
Why?
|
| Serum Albumin | 1 | 2012 | 45 | 0.100 |
Why?
|
| Vital Capacity | 1 | 2012 | 105 | 0.100 |
Why?
|
| Carbon Dioxide | 1 | 2012 | 81 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 278 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2013 | 461 | 0.100 |
Why?
|
| Anesthesia, Local | 1 | 2011 | 20 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 193 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2018 | 1203 | 0.090 |
Why?
|
| Hypnotics and Sedatives | 1 | 2011 | 62 | 0.090 |
Why?
|
| Analgesia | 1 | 2011 | 30 | 0.090 |
Why?
|
| Anesthetics, Local | 1 | 2011 | 67 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 202 | 0.090 |
Why?
|
| Analgesics | 1 | 2011 | 96 | 0.090 |
Why?
|
| Educational Measurement | 1 | 2012 | 212 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 339 | 0.090 |
Why?
|
| Risk Factors | 4 | 2014 | 4985 | 0.090 |
Why?
|
| Acute Disease | 1 | 2012 | 658 | 0.090 |
Why?
|
| Risk | 2 | 2021 | 364 | 0.090 |
Why?
|
| Career Mobility | 2 | 2020 | 62 | 0.080 |
Why?
|
| Palliative Care | 2 | 2018 | 214 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1051 | 0.080 |
Why?
|
| Tracheal Stenosis | 1 | 2008 | 9 | 0.080 |
Why?
|
| Faculty, Medical | 2 | 2023 | 192 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 527 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 735 | 0.070 |
Why?
|
| Benchmarking | 2 | 2023 | 135 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 1557 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 628 | 0.070 |
Why?
|
| Respiratory Mucosa | 1 | 2007 | 54 | 0.070 |
Why?
|
| Intubation, Intratracheal | 1 | 2008 | 194 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2021 | 3065 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2019 | 5280 | 0.060 |
Why?
|
| Stents | 2 | 2009 | 461 | 0.060 |
Why?
|
| Bronchial Neoplasms | 1 | 2004 | 6 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2021 | 2375 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2004 | 21 | 0.060 |
Why?
|
| Airway Obstruction | 1 | 2004 | 37 | 0.060 |
Why?
|
| Comorbidity | 2 | 2020 | 1078 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 474 | 0.060 |
Why?
|
| Bronchi | 2 | 2019 | 82 | 0.050 |
Why?
|
| Radiation Dosage | 2 | 2015 | 126 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 717 | 0.050 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2023 | 37 | 0.050 |
Why?
|
| Quality of Life | 2 | 2021 | 1137 | 0.050 |
Why?
|
| Massachusetts | 2 | 2020 | 2019 | 0.050 |
Why?
|
| Recurrence | 2 | 2017 | 602 | 0.050 |
Why?
|
| Citalopram | 1 | 2021 | 19 | 0.050 |
Why?
|
| Long QT Syndrome | 1 | 2021 | 30 | 0.040 |
Why?
|
| Denmark | 1 | 2020 | 16 | 0.040 |
Why?
|
| Incidence | 2 | 2014 | 1238 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 164 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 168 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2014 | 5137 | 0.040 |
Why?
|
| Body Composition | 1 | 2020 | 146 | 0.040 |
Why?
|
| Inhalation | 1 | 2019 | 10 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 2338 | 0.040 |
Why?
|
| Specialization | 1 | 2020 | 78 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 451 | 0.040 |
Why?
|
| Time Factors | 2 | 2017 | 3615 | 0.040 |
Why?
|
| Adult | 5 | 2021 | 15696 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 143 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2021 | 206 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2021 | 521 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2018 | 180 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 136 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 163 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1523 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2018 | 207 | 0.030 |
Why?
|
| Deep Sedation | 1 | 2016 | 4 | 0.030 |
Why?
|
| Lymphatic Diseases | 1 | 2016 | 13 | 0.030 |
Why?
|
| Hamartoma | 1 | 2015 | 7 | 0.030 |
Why?
|
| Mediastinoscopy | 1 | 2015 | 7 | 0.030 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2015 | 16 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2009 | 554 | 0.030 |
Why?
|
| Thoracotomy | 1 | 2015 | 44 | 0.030 |
Why?
|
| Granuloma | 1 | 2015 | 41 | 0.030 |
Why?
|
| Simulation Training | 1 | 2016 | 62 | 0.030 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2015 | 54 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 1925 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 244 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 249 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 415 | 0.030 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2013 | 3 | 0.030 |
Why?
|
| North America | 1 | 2013 | 105 | 0.030 |
Why?
|
| Australia | 1 | 2013 | 86 | 0.030 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2014 | 75 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2013 | 28 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 442 | 0.030 |
Why?
|
| Europe | 1 | 2013 | 182 | 0.030 |
Why?
|
| Heterografts | 1 | 2013 | 61 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 160 | 0.030 |
Why?
|
| Interdisciplinary Studies | 1 | 2012 | 7 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 85 | 0.030 |
Why?
|
| Radiology Information Systems | 1 | 2013 | 31 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2012 | 39 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2013 | 92 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 133 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 392 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 332 | 0.020 |
Why?
|
| Cell Survival | 1 | 2014 | 559 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 205 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1091 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 801 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 486 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2015 | 540 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 902 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 453 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1597 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 1234 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 724 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 526 | 0.020 |
Why?
|
| Equipment Design | 1 | 2009 | 329 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2013 | 648 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2010 | 914 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 294 | 0.020 |
Why?
|
| Prosthesis Fitting | 1 | 2004 | 7 | 0.010 |
Why?
|
| Hemoptysis | 1 | 2004 | 8 | 0.010 |
Why?
|
| Foreign-Body Migration | 1 | 2004 | 20 | 0.010 |
Why?
|
| Device Removal | 1 | 2004 | 64 | 0.010 |
Why?
|
| Dyspnea | 1 | 2004 | 116 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 248 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 2004 | 209 | 0.010 |
Why?
|
| Cough | 1 | 2004 | 183 | 0.010 |
Why?
|
| Biomarkers | 1 | 2007 | 1306 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 10286 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 19642 | 0.010 |
Why?
|